Genentech access to 23andMe genetic and phenotypic database for Parkinson's target discovery

$10 million upfront

USD upfront per deal (one contract), US

“The big biotech has reportedly paid $10 million upfront and agreed to $50 million in milestones to access 23andMe's database for target discovery of new drugs for Parkinson's disease”

Fierce Biotech, 23andMe strikes $60M Genentech deal to continue pivot to database-driven R&D (12 January 2015), 2015-01

Kind of source: Named press report
Read on: 2026-11-06
Daily check: Source re-read on 2026-11-06 needs a browser (PDF or protected page)
What to know: Reported terms (the companies did not publish them). The $50 million in milestones is conditional. Genentech also pays for whole genome sequencing of 3,000 people in the database, so the upfront sum is not a per-genome price.
About: Parkinson's disease Consumer DNA test Whole genome or exome

Used in

Kept as evidence; no figure on the platform is computed from it yet.